HBV-X
Greater than 95% as determined by SDS-PAGE.
Description
Hepatitis B Virus Protein X is a 17kDa protein containing 154 amino acid residues and purified by proprietary chromatographic techniques.
Product Specs
The Hepatitis B Virus Protein X is a 17kDa protein comprised of 154 amino acids. It undergoes purification using specialized chromatographic techniques.
SDS-PAGE analysis indicates a purity exceeding 95%.
The product is subjected to filtration (0.4µm) and lyophilization. The lyophilization process is carried out from a solution containing 0.5mg/ml of the protein in a 30mM acetate buffer with a pH of 4 and 5% trehalose.
MAARVCCQLD PARDVLCLRP VGAESRGRPV SGPFGTLPSP SSSAVPADHG AHLSLRGLPV CAFSSAGPCA LRFTSARRME TTVNAHQVLP KVLHKRTLGL SAMSTTDLEA YFKDCLFKDW EELGEEIRLK VFVLGGCRHK LVCSPAPCNF FTSA.
Product Science Overview
Hepatitis B Virus (HBV) is a significant global health concern, with approximately 250 million people living with chronic HBV infection worldwide . The virus is primarily transmitted through exposure to infected blood or other body fluids, leading to severe liver diseases such as cirrhosis and hepatocellular carcinoma .
The HBV x Recombinant refers to the use of recombinant DNA technology to produce HBV antigens, particularly the HBV X protein (HBx). HBx is a regulatory protein that plays a crucial role in the viral life cycle and pathogenesis. It is involved in viral replication, transcriptional regulation, and modulation of host immune responses .
The first recombinant HBV vaccine was developed in the 1980s, replacing the earlier plasma-derived vaccines. The recombinant vaccine is produced by inserting the gene encoding the HBV surface antigen (HBsAg) into yeast cells, which then express the antigen. The antigen is purified and used to formulate the vaccine .
Recombinant HBV vaccines have been highly effective in reducing the incidence of HBV infection and associated liver diseases. They have a strong safety profile and are recommended for all children worldwide, with a birth dose ideally administered within 24 hours of birth .
Recent research has focused on the therapeutic potential of HBx in treating chronic HBV infection. HBx-based therapeutic vaccines aim to enhance the immune response against HBV by inducing HBx-specific T cell responses. Studies have shown that HBx-based vaccines can significantly reduce viral load and promote the clearance of infected hepatocytes .
